Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Front Immunol
2019 Apr 04;10:664. doi: 10.3389/fimmu.2019.00664.
Show Gene links
Show Anatomy links
SLPI Inhibits ATP-Mediated Maturation of IL-1β in Human Monocytic Leukocytes: A Novel Function of an Old Player.
Zakrzewicz A
,
Richter K
,
Zakrzewicz D
,
Siebers K
,
Damm J
,
Agné A
,
Hecker A
,
McIntosh JM
,
Chamulitrat W
,
Krasteva-Christ G
,
Manzini I
,
Tikkanen R
,
Padberg W
,
Janciauskiene S
,
Grau V
.
???displayArticle.abstract???
Interleukin-1β (IL-1β) is a potent, pro-inflammatory cytokine of the innate immune system that plays an essential role in host defense against infection. However, elevated circulating levels of IL-1β can cause life-threatening systemic inflammation. Hence, mechanisms controlling IL-1β maturation and release are of outstanding clinical interest. Secretory leukocyte protease inhibitor (SLPI), in addition to its well-described anti-protease function, controls the expression of several pro-inflammatory cytokines on the transcriptional level. In the present study, we tested the potential involvement of SLPI in the control of ATP-induced, inflammasome-dependent IL-1β maturation and release. We demonstrated that SLPI dose-dependently inhibits the ATP-mediated inflammasome activation and IL-1β release in human monocytic cells, without affecting the induction of pro-IL-1β mRNA by LPS. In contrast, the ATP-independent IL-1β release induced by the pore forming bacterial toxin nigericin is not impaired, and SLPI does not directly modulate the ion channel function of the human P2X7 receptor heterologously expressed in Xenopus laevis oocytes. In human monocytic U937 cells, however, SLPI efficiently inhibits ATP-induced ion-currents. Using specific inhibitors and siRNA, we demonstrate that SLPI activates the calcium-independent phospholipase A2β (iPLA2β) and leads to the release of a low molecular mass factor that mediates the inhibition of IL-1β release. Signaling involves nicotinic acetylcholine receptor subunits α7, α9, α10, and Src kinase activation and results in an inhibition of ATP-induced caspase-1 activation. In conclusion, we propose a novel anti-inflammatory mechanism induced by SLPI, which inhibits the ATP-dependent maturation and secretion of IL-1β. This novel signaling pathway might lead to development of therapies that are urgently needed for the prevention and treatment of systemic inflammation.
Adapala,
Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet.
2011, Pubmed
Adapala,
Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet.
2011,
Pubmed
Amati,
Chemokines (CCL3, CCL4, and CCL5) Inhibit ATP-Induced Release of IL-1β by Monocytic Cells.
2017,
Pubmed
Ashcroft,
Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing.
2000,
Pubmed
Backhaus,
Surfactant inhibits ATP-induced release of interleukin-1β via nicotinic acetylcholine receptors.
2017,
Pubmed
Balsinde,
Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages.
1995,
Pubmed
Bharadwaj,
Annexin A2 heterotetramer: structure and function.
2013,
Pubmed
Burke,
Phospholipase A2 biochemistry.
2009,
Pubmed
Cekic,
Purinergic regulation of the immune system.
2016,
Pubmed
Cogswell,
NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site.
1994,
Pubmed
Costa-Junior,
C terminus of the P2X7 receptor: treasure hunting.
2011,
Pubmed
Dasgupta,
Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story.
2006,
Pubmed
Deng,
iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
2016,
Pubmed
Denlinger,
Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide.
2001,
Pubmed
Dinarello,
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
2012,
Pubmed
Dinarello,
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.
2011,
Pubmed
Ding,
Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages.
1999,
Pubmed
Di Virgilio,
The P2X7 Receptor in Infection and Inflammation.
2017,
Pubmed
Doumas,
Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.
2005,
Pubmed
Greene,
TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells.
2005,
Pubmed
Greene,
Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells.
2004,
Pubmed
Grobmyer,
Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia.
2000,
Pubmed
Gross,
The inflammasome: an integrated view.
2011,
Pubmed
Guo,
Inflammasomes: mechanism of action, role in disease, and therapeutics.
2015,
Pubmed
Hecker,
Phosphocholine-Modified Macromolecules and Canonical Nicotinic Agonists Inhibit ATP-Induced IL-1β Release.
2015,
Pubmed
Hiemstra,
Defensins and cathelicidins in inflammatory lung disease: beyond antimicrobial activity.
2006,
Pubmed
Hiller,
β-Nicotinamide Adenine Dinucleotide (β-NAD) Inhibits ATP-Dependent IL-1β Release from Human Monocytic Cells.
2018,
Pubmed
Hung,
Roles of protein kinase C in regulation of P2X7 receptor-mediated calcium signalling of cultured type-2 astrocyte cell line, RBA-2.
2005,
Pubmed
Innocent,
Alpha-conotoxin Arenatus IB[V11L,V16D] [corrected] is a potent and selective antagonist at rat and human native alpha7 nicotinic acetylcholine receptors.
2008,
Pubmed
,
Xenbase
Jin,
Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor.
1998,
Pubmed
Jin,
Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide.
1997,
Pubmed
Kabbani,
Beyond the Channel: Metabotropic Signaling by Nicotinic Receptors.
2018,
Pubmed
Kabbani,
Are nicotinic acetylcholine receptors coupled to G proteins?
2013,
Pubmed
Kim,
Proteomic and functional evidence for a P2X7 receptor signalling complex.
2001,
Pubmed
King,
A G protein-coupled α7 nicotinic receptor regulates signaling and TNF-α release in microglia.
2017,
Pubmed
King,
Identification and Characterization of a G Protein-binding Cluster in α7 Nicotinic Acetylcholine Receptors.
2015,
Pubmed
Kudryavtsev,
Natural compounds interacting with nicotinic acetylcholine receptors: from low-molecular weight ones to peptides and proteins.
2015,
Pubmed
Ma,
Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection.
2004,
Pubmed
Marchetti,
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.
2018,
Pubmed
Marino,
Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice.
2011,
Pubmed
McIntosh,
Alpha9 nicotinic acetylcholine receptors and the treatment of pain.
2009,
Pubmed
,
Xenbase
Moreau,
Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family.
2008,
Pubmed
Nakamura,
Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice.
2003,
Pubmed
Nukiwa,
Secretory leukocyte peptidase inhibitor and lung cancer.
2008,
Pubmed
Ozaki,
Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives.
2015,
Pubmed
Philip,
The nicotinic acetylcholine receptor as a target for antidepressant drug development.
2012,
Pubmed
Prompunt,
The cardioprotective effects of secretory leukocyte protease inhibitor against myocardial ischemia/reperfusion injury.
2018,
Pubmed
Ramanadham,
Calcium-independent phospholipases A2 and their roles in biological processes and diseases.
2015,
Pubmed
Rathinam,
Regulation of inflammasome signaling.
2012,
Pubmed
Rescher,
Annexins--unique membrane binding proteins with diverse functions.
2004,
Pubmed
Richter,
C-Reactive Protein Stimulates Nicotinic Acetylcholine Receptors to Control ATP-Mediated Monocytic Inflammasome Activation.
2018,
Pubmed
Richter,
Phosphocholine - an agonist of metabotropic but not of ionotropic functions of α9-containing nicotinic acetylcholine receptors.
2016,
Pubmed
,
Xenbase
Romero,
Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.
2017,
Pubmed
Sallenave,
Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes.
1994,
Pubmed
Savio,
The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
2018,
Pubmed
Scott,
SLPI and elafin: multifunctional antiproteases of the WFDC family.
2011,
Pubmed
Siebers,
Alpha-1 Antitrypsin Inhibits ATP-Mediated Release of Interleukin-1β via CD36 and Nicotinic Acetylcholine Receptors.
2018,
Pubmed
Street,
Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2.
1993,
Pubmed
Taggart,
Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination.
2002,
Pubmed
Taggart,
Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding.
2005,
Pubmed
Vladimer,
Inflammasomes and host defenses against bacterial infections.
2013,
Pubmed
Vogelmeier,
Comparative loss of activity of recombinant secretory leukoprotease inhibitor and alpha 1-protease inhibitor caused by different forms of oxidative stress.
1997,
Pubmed
Weldon,
The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses.
2007,
Pubmed
Williams,
SLPI and elafin: one glove, many fingers.
2006,
Pubmed
Zakrzewicz,
Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10.
2017,
Pubmed
